Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) fell 0% during trading on Friday . The stock traded as low as $2.31 and last traded at $2.41. 3,304,048 shares were traded during trading, an increase of 141% from the average session volume of 1,372,324 shares. The stock had previously closed at $2.41.

Several brokerages recently commented on INFI. Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. ValuEngine raised shares of Infinity Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, October 12th. Finally, Wells Fargo & Company raised shares of Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Thursday, October 12th.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $14.70 million. During the same period in the previous year, the firm posted ($0.39) EPS. sell-side analysts forecast that Infinity Pharmaceuticals, Inc. will post -0.98 earnings per share for the current fiscal year.

In other Infinity Pharmaceuticals news, insider Value Fund L. P. Biotechnology acquired 1,600,046 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was purchased at an average price of $1.26 per share, with a total value of $2,016,057.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 6.81% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Infinity Pharmaceuticals by 27.7% in the 1st quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after purchasing an additional 1,021,128 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Infinity Pharmaceuticals by 32.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 652,481 shares of the biotechnology company’s stock valued at $1,024,000 after purchasing an additional 160,814 shares during the period. Legal & General Group Plc boosted its holdings in Infinity Pharmaceuticals by 2,430.0% in the 2nd quarter. Legal & General Group Plc now owns 349,346 shares of the biotechnology company’s stock valued at $548,000 after purchasing an additional 335,538 shares during the period. Geode Capital Management LLC boosted its holdings in Infinity Pharmaceuticals by 4.5% in the 1st quarter. Geode Capital Management LLC now owns 345,366 shares of the biotechnology company’s stock valued at $1,114,000 after purchasing an additional 15,005 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Infinity Pharmaceuticals by 75.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 246,234 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 105,497 shares during the period. 67.12% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/infinity-pharmaceuticals-inc-infi-trading-down-0/1694344.html.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.